Patents by Inventor Hikaru Yabuuchi

Hikaru Yabuuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10994056
    Abstract: A device for fixing biological soft tissue is endowed with strength and deformation performance for being used as a device for coupling biological soft tissue that has been cut or separated due to an incision or the like during a surgical procedure, and is completely degraded in vivo and discharged after adhesion of the soft tissue or after healing of the incision tissue. The device is composed of a ternary Mg alloy material of Mg—Ca—Zn. In the Mg alloy material, the Ca and Zn are contained within the solid-solubility limit with respect to the Mg. The remainder is composed of Mg and unavoidable impurities. The Zn content is 0.5 at % or less. The Ca and Zn content has a relationship of Ca:Zn=1:x (where x is 1 to 3) by atom ratio. The crystal grain structure is equiaxed, the crystal grain size according to linear intercept being 30 to 250 ?m.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: May 4, 2021
    Assignee: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
    Inventors: Toshiji Mukai, Naoko Ikeo, Eisei Gu, Takumi Fukumoto, Hikaru Yabuuchi
  • Publication number: 20170258968
    Abstract: A device for fixing biological soft tissue is endowed with strength and deformation performance for being used as a device for coupling biological soft tissue that has been cut or separated due to an incision or the like during a surgical procedure, and is completely degraded in vivo and discharged after adhesion of the soft tissue or after healing of the incision tissue. The device is composed of a ternary Mg alloy material of Mg—Ca—Zn. In the Mg alloy material, the Ca and Zn are contained within the solid-solubility limit with respect to the Mg. The remainder is composed of Mg and unavoidable impurities. The Zn content is 0.5 at % or less. The Ca and Zn content has a relationship of Ca:Zn=1:x (where x is 1 to 3) by atom ratio. The crystal grain structure is equiaxed, the crystal grain size according to linear intercept being 30 to 250 ?m.
    Type: Application
    Filed: September 9, 2015
    Publication date: September 14, 2017
    Inventors: Toshiji MUKAI, Naoko IKEO, Eisei GU, Takumi FUKUMOTO, Hikaru YABUUCHI
  • Publication number: 20060141496
    Abstract: The present invention relates to a method for measuring transporter activity of ABC protein that may measure not only small amount of samples with small data fluctuation and good reproducibility, but also many samples simultaneously and concisely; a screening method for substances that interact with ABC protein using said measuring method; and a kit for measuring transporter activity of ABC protein that may advantageously be used for those methods. Pre-incubation may be carried out by adding the insect cellular membrane expressing human P-glycoprotein to the reaction buffer solution including vanadic acid and [3H] ATP. Following this, the test compound may be added for reaction, after which reaction liquid may be added to a glass filter of 96-well type, and by using the suction cleaning method, adsorption amount of [3H] ADP into the membrane-expressing P-glycoprotein may be measured in a single step.
    Type: Application
    Filed: September 23, 2005
    Publication date: June 29, 2006
    Inventors: Hikaru Yabuuchi, Toshihisa Ishikawa
  • Publication number: 20040137573
    Abstract: This invention relates to human vanilloid receptor-like protein 2 (VRL-2) polypeptides, polynucleotides encoding such polypeptides, polynucleotide probes or primers, expression vectors and host cells comprising such DNA molecules. This invention further relates to a process for producing the polypeptides; an antibody immunospecific for the polypeptide; a diagnostic kit for diagnosing the VRL-2 receptor related disease; a method for screening to identify modulators which modulate the polypeptides; modulators identified by the screening method; a pharmaceutical composition for treatment of conditions associated with biological function of the polypeptides; and a non-human transgenic animal model for vanilloid receptor-like gene. The polypeptides and the DNA molecules of the present invention can be used to identify agonists, antagonists or the like.
    Type: Application
    Filed: January 20, 2004
    Publication date: July 15, 2004
    Inventors: Katsuhiro Shinjo, Hikaru Yabuuchi
  • Publication number: 20030017527
    Abstract: This invention relates to human vanilloid receptor-like protein 2 (VRL-2) polypeptides, polynucleotides encoding such polypeptides, polynucleotide probes or primers, expression vectors and host cells comprising such DNA molecules. This invention further relates to a process for producing the polypeptides; an antibody immunospecific for the polypeptide; a diagnostic kit for diagnosing the VRL-2 receptor related disease; a method for screening to identify modulators which modulate the polypeptides; modulators identified by the screening method; a pharmaceutical composition for treatment of conditions associated with biological function of the polypeptides; and a non-human transgenic animal model for vanilloid receptor-like gene. The polypeptides and the DNA molecules of the present invention can be used to identify agonists, antagonists or the like.
    Type: Application
    Filed: May 30, 2001
    Publication date: January 23, 2003
    Inventors: Katsuhiro Shinjo, Hikaru Yabuuchi